San Diego, USA-based Neurocrine Biosciences today announced the launch of its Crenessity (crinecerfont) in the USA.

Epitopea partners with Genevant Sciences to develop RNA-based cancer immunotherapies targeting proprietary tumor antigens.

UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...

US biotech Regeneron Pharmaceuticals has announced positive Phase II results for two novel monoclonal antibodies targeting ...

Zealand Pharma faces a setback as the FDA issues a complete response letter for glepaglutide, requiring a new Phase III trial ...

Astellas Pharma partners with Sangamo Therapeutics to license STAC-BBB, a neurotropic AAV capsid for neurological disease ...

Swiss pharma giant Novartis (NOVN: VX) is to shut two sites belonging to its MorphoSys unit. The facilities in Munich, ...

Denmark’s Novo Nordisk today announced headline results from REDEFINE 1, a Phase III trial in the global REDEFINE program, ...

The US Food and Drug Administration (FDA) has approved Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in ...

US pharma giant Merck has announced top-line results from two pivotal Phase III trials of the investigational, once-daily, ...

US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) today recommending Pedmarqsi ...